Rechercher
Developing and implementing a Drug reduce University Diploma for health practitioners in Uruguay: challenges and future directions
In Uruguay, there is a shortage of trained professionals in drug prevention, intervention, and resolution of drug-related issues, particularly among health personnel in domains such as rehabilitation, prevention, schools, communities, and...
ATI Basics: SUD Treatment for Persons in the Justice System
Developing and implementing a Drug reduce University Diploma for health practitioners in Uruguay: challenges and future directions
ATI Basics: Fundamentals of Alternatives to Incarceration (ATI)
Can a "treatment specialist" also be seen as a "prevention specialist" and vice versa?
Pharmacological and Behavioral Treatment of Opioid Use Disorder
Abstract
Objective:
Opioid use disorder (OUD) in the United States has surged, with an estimated 2.5 million needing treatment. The aim of this article is to provide a clinical overview of the key pharmacological and behavioral treatments...
ATI Basics: Why Alternatives to Incarceration (ATI)?
Continental Training of Trainers (ToT) on the CHILD Curriculum and In-Person Training in Egypt
Children's drug use in Africa is a growing concern that requires urgent attention and comprehensive strategies. Understanding the complex factors influencing children's drug use and implementing effective prevention and intervention...
Continental Training of Trainers (ToT) on the CHILD Curriculum and In-Person Training in Egypt
Children's drug use in Africa is a growing concern that requires urgent attention and comprehensive strategies. Understanding the complex factors influencing children's drug use and implementing effective prevention and intervention...
Intervenciones en trastornos por usos de sustancias (TUS): una mirada desde la Psicología y la Neurociencia
Stimulant Use Webinar Series. Part I: About Amphetamine Type Stimulants and Stimulant Use Disorder
Pharmacological management of acute methamphetamine withdrawal
About the webinar:
This seminar provided an overview of Liam’s PhD studies, beginning with a systematic review and meta-analysis of previously researched pharmacological treatments for methamphetamine withdrawal.
It then proposed a novel...
Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder
Abstract
Importance Suicidal behavior is a significant clinical concern in individuals with borderline personality disorder (BPD), but the effectiveness of pharmacotherapy on reducing suicide risk has remained unknown.
Objective To...
Les psychédéliques favorisent la plasticité en se liant directement au récepteur BDNF TrkB
Abstrait
Les psychédéliques produisent des effets antidépresseurs rapides et persistants et induisent une neuroplasticité ressemblant aux effets des antidépresseurs cliniquement approuvés. Nous avons récemment rapporté que des...
How alcohol consumption contributes to chronic pain
A team showed how both alcohol intake and alcohol withdrawal can lead to increased pain and hypersensitivity.
Chronic alcohol consumption may make people more sensitive to pain through two different molecular mechanisms -- one driven by...
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
La FDA approuve une nouvelle option de traitement à la buprénorphine pour le trouble lié à l’utilisation d’opioïdes
Pour diffusion immédiate : 24 mai 2023
Aujourd’hui, la Food and Drug Administration (FDA) des États-Unis a approuvé l’injection sous-cutanée à libération prolongée de Brixadi (buprénorphine) pour traiter les troubles modérés à graves liés...
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review
Abstract
Objective
The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration–approved medications for treatment of opioid use disorder: methadone, buprenorphine...
L’activation focale des récepteurs mu-opioïdes favorise la neuroinflammation et l’activation microgliale dans le système mésocorticolimbique : Altérations induites par la douleur inflammatoire
Abstrait
La microglie participe à la modulation de la signalisation de la douleur. Il est suggéré que l’activation de la microglie joue un rôle important dans les troubles affectifs liés à un dysfonctionnement du système...